AI ECoG Assistant

ECoG ASSISTANT™

Treatment Insights Simplified

ECoG Assistant is the first FDA-approved NeuroPace AI application to streamline the iEEG review process in PDMS, empowering clinicians to uncover actionable insights for informed confident care with the RNS® System.

Identify ECoGs of Interest1 with 93% Sensitivity2

Trends Instantly

With one click, the Trends Report reveals the count of ECoGs of Interest over months, facilitating efficient patient assessments.

Timing Effortlessly

The Circadian Pattern chart highlights when ECoGs of Interest occurred by time of day, providing context to explore potential triggers and medication timing.

Quickly Identify ECoGs of Interest

Improved ECoG Library user interface allows you to easily identify & count ECoGs of Interest with the one-click AI-Powered toggle.

Life-Changing Outcomes

3 Year Median Seizure Reduction (%)

40% DBS

MORE Registry4(n=101)

44% VNS

Study Group E01-E053(n=93)

82% RNS®
System

Post Approval Study(n=255)

LONG-TERM SEIZURE REDUCTION

82%

median seizure reduction at 3 years3, 4, 5

Combining the world's largest intracranial EEG dataset with the transformative power of Ai to develop the next generation of clinical tools, enabling more confident, personalized epilepsy care for every patient.

Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important prescribing and safety information at www.NeuroPace.com/safety. Refer to the labeling for a description of the RNS System and its components, indications for use, contraindications, warnings, cautions, adverse events and instructions for use.

  1. ECoGs of Interest are iEEG records identified by ECoG Assistant as likely to contain electrographic seizures. ECoG Assistant was developed on over 124,000 expert-labeled iEEG long episode records and validated against a three-epileptologist consensus standard for electrographic seizures.
  2. Sensitivity is the proportion of iEEG records correctly identified by ECoG Assistant as likely to contain electrographic seizures, out of those labeled as containing electrographic seizures by 3 board-certified epileptologists.
  3. RNS System Post-approval Study Oral Presentation, American Academy of Neurology, April 2025, all outcomes are ITT, median seizure reduction is observed case data.
  4. Eliashiv, D. et al. Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy, Three-year Efficacy and Interim Safety Results. Neurology 2026;106:e214875
  5. Morris et al, Neurology, 1999 5. Kaufmann et al., Epilepsia, 2024
NOTE: Therapies were studied using different study designs. Caution must be exercised when comparing results.

© 2026 NeuroPace, Inc. All rights reserved. NeuroPace and RNS are registered trademarks of NeuroPace, Inc., Mountain View, CA
NP 250149Rev2 / Rev Date 2026-5